Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 10/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140969 | 0.93 | TYMP (0.50) | TYMPADORA1NT5E | |
| SCHEMBL30141046 | 0.93 | TYMP (0.47) | TYMPADORA1NT5ECA5ALMNA | |
| SCHEMBL30140976 | 0.92 | TYMP (0.47) | TYMPADORA1NT5ECA5ALMNA | |
| SCHEMBL7615059 | 0.86 | TYMP (0.59) | TYMPADORA1NT5ECA5ALMNA | |
| SCHEMBL7615063 | 0.86 | TYMP (0.59) | TYMPADORA1NT5ECA5ALMNA | |
| SCHEMBL30140978 | 0.85 | TYMP (0.45) | TYMPADORA1NT5ECA5AADORA2A | |
| SCHEMBL29793139 | 0.84 | TYMP (0.58) | TYMPADORA1LMNA | |
| SCHEMBL7895839 | 0.83 | TYMP (0.69) | TYMPADORA1NT5ECA5ALMNA | |
| SCHEMBL3803391 | 0.82 | TYMP (0.54) | TYMPADORA1NT5E | |
| SCHEMBL1895610 | 0.81 | TYMP (0.60) | TYMPADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | TYMP 76/4885ADORA1 107/4885NT5E 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.